Zura Bio Acquires Cellarity Assets
Ticker: ZURA · Form: 8-K · Filed: May 29, 2024 · CIK: 1855644
| Field | Detail |
|---|---|
| Company | Zura Bio Ltd (ZURA) |
| Form Type | 8-K |
| Filed Date | May 29, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, pipeline-expansion, biotech
TL;DR
Zura Bio buying Cellarity assets, Q3 close.
AI Summary
Zura Bio Ltd. announced on May 29, 2024, that it has entered into a definitive agreement to acquire certain assets from Cellarity Limited. The transaction is expected to close in the third quarter of 2024. This acquisition aims to expand Zura Bio's pipeline and therapeutic capabilities.
Why It Matters
This acquisition could significantly bolster Zura Bio's drug development pipeline, potentially leading to new therapeutic options for patients.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, regulatory approval, and achieving projected synergies.
Key Players & Entities
- Zura Bio Ltd. (company) — Registrant
- Cellarity Limited (company) — Seller of assets
- May 29, 2024 (date) — Date of report
- third quarter of 2024 (date) — Expected closing period
FAQ
What specific assets is Zura Bio acquiring from Cellarity Limited?
The filing does not specify the exact assets being acquired, only that it is 'certain assets'.
What is the financial value of this acquisition?
The filing does not disclose the financial terms or dollar amount of the acquisition.
When is the acquisition expected to be completed?
The acquisition is expected to close in the third quarter of 2024.
What is the strategic rationale behind this acquisition for Zura Bio?
The filing implies the acquisition aims to expand Zura Bio's pipeline and therapeutic capabilities, though specific details are not provided.
Has Zura Bio Ltd. undergone any previous name changes?
Yes, Zura Bio Ltd. was formerly known as JATT Acquisition Corp, with a name change on April 7, 2021.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-29 06:05:16
Key Financial Figures
- $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
- $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma
Filing Documents
- tm2415774d1_8k.htm (8-K) — 31KB
- tm2415774d1_ex99-1.htm (EX-99.1) — 5KB
- tm2415774d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-065741.txt ( ) — 258KB
- zura-20240529.xsd (EX-101.SCH) — 3KB
- zura-20240529_def.xml (EX-101.DEF) — 26KB
- zura-20240529_lab.xml (EX-101.LAB) — 36KB
- zura-20240529_pre.xml (EX-101.PRE) — 25KB
- tm2415774d1_8k_htm.xml (XML) — 5KB
01
Item 7.01. Regulation FD Disclosure. On May 29, 2024, Zura Bio Limited issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated May 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 29, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer